E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients scheduled for elective laparoscopic radical prostatectomy surgery |
Pacientes programados para cirugía de prostatectomía radical laparoscópica |
|
E.1.1.1 | Medical condition in easily understood language |
Patients scheduled for elective laparoscopic radical prostatectomy surgery |
Pacientes programados para cirugía de prostatectomía radical laparoscópica |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the effectiveness of the US-guided bilateral TAP block tecnique as part of a multimodal analgesic plan that reduces the postoperative pain in the laparoscopic radical prostatectomy surgery compared with the IV conventional analgesia |
Evaluar la eficacia del bloqueo TAP bilateral ecoguiado como parte de una estrategia de analgesia multimodal que disminuya el dolor postoperatorio en la cirugía de prostatectomía radical laparoscópica comparada con la analgesia IV convencional. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
No aplicable |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- ASA physical status I-III
- Male
- Aged 18-90 years
- Scheduled for elective laparoscopic radical prostatectomy
- Able to provide written informed consent |
-ASA I-III
-Varón
-Edad de 18-90 años
-Programados para cirugía de prostatectomía radical laparoscópica
-Capaces de firmar el consentimiento informado |
|
E.4 | Principal exclusion criteria |
- Unable to provide written informed consent
- Unable to understand the Visual Analog Scale (VAS) for pain
- Allergy to local anesthetic agents or other drug of the study
- Preoperative chronic dependence upon opioid medication
- Contraindication for TAP block: Coagulopathy, use of anticoagulant drugs or infection of the point of injection |
-Incapaz de firmar el consentimiento informado-
-Incapaz de comprender la escala visual analógica EVA de dolor
-Alérgico a anestésicos locales u otros fármacos del estudio
-Dependencia crónica a Opioides
-Contraindicación para el bloqueo TAP: coagulopatía, uso de fármacos anticoagulantes, infección en el punto de inyección. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Decrease the intensity of postoperative pain after laparoscopic radical prostatectomy surgery, measured with the VAS scale |
-Reducción de la intensidad del dolor postoperatorio después de cirugía de prostatectomía radical laparoscópica medido mediante escala EVA |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
First 48 hours of postoperative period |
Primeras 48 horas del postoperatorio |
|
E.5.2 | Secondary end point(s) |
- Increase the time to first request for rescue analgesia in the postoperative period
- Decrease postoperative nausea and vomiting
- Decrease postoperative opioid consumption |
-Incrementar el tiempo requerido hasta el primer rescate analgésico en el periodo postoperatorio.
-Disminuir las náuseas y vómitos postoperatorios.
-Dismunuir el consumo de opioide postoperatorio. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
First 48 hours of postoperative period |
Primeras 48 horas postoperatorias. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Conventional iv analgesic therapy |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |